The study by Remeijer et al. [1] conducted at the Rotterdam Eye Hospital in The Netherlands and reported in this issue of the Journal significantly enhances our knowledge of herpes simplex virus type 1 (HSV-1) DNA in human corneas and provides important clinical information about the consequences of HSV-1 DNA in the cornea. Patient medical records were reviewed for relevant clinical information, including data on graft survival after penetrating keratoplasty (PKP). HSV-1 DNA, as quantified by real-time polymerase chain reaction (PCR), was detected in 40 (48%) of 83 patients with a history of herpetic keratitis (HK; hereafter referred to as "patients with HK") and in 15 (4%) of 367 patients without a history of HK (hereafter referred to as "patients without HK") (table 1). HSV-1 DNA copies in all corneas were quantified, and the corneas of patients with HK were found to contain ∼100 times more virus than the corneas of patients without HK. Furthermore, the corneal HSV-1 DNA load correlated with increased age both in patients with HK and in patients without HK. Steroid use before PKP was also found to increase the viral load.
Graft survival was not statistically different between patients with HK (56 [67%] of 83 patients) and patients without HK (260 [71%] of 367 patients). Although the presence or absence of HSV-1 DNA was not correlated with graft failure, the viral load in patients with HK was associated with a lack of success. This finding leads us to the question, How does a higher viral load increase graft failure?
The rate of graft failure among patients with HK who had high viral loads suggests the following 3 possibilities. The first possibility is that the patients harbored in their neurons a latent strain of HSV-1 that could be characterized as a high phenotypic reactivator. High phenotypic reactivators are known to undergo significantly more reactivation episodes than low phenotypic reactivators [8, 9] . The second possibility is that the corneal rim in the transplant recipient contained an amount of HSV-1 DNA sufficient to initiate replication, migrate to the transplanted cornea, reactivate, and initiate an immune response, leading to graft rejection. The third possibility is a combination of the first 2 possibilities.
Graft failure occurred in patients with HK who were receiving intense antiviral and anti-inflammatory therapy both preoperatively and postoperatively [10, 11] . This long-term combination therapy is often unsuccessful in patients with chronic HK (also known as "herpetic stromal keratitis"), thus highlighting the need for new combination therapies for this blinding disease of the eye [10] . Preoperative steroid treatment before PKP significantly increased the viral load in the recipient corneas and decreased the success rate after PKP [1] . These findings confirmed previous reports of the hazardous effects of steroid therapy on the corneas of patients with HK [10, 11] .
Good news, problems, and dilemmas abound regarding chemotherapy for epithelial HSV-1 keratitis, HK, and chronic HK. The good news is that the majority (90%-95%) of cases of ocular herpes are unilateral. The other good news is that topical and systemic antiherpetic drugs for ocular herpes are very effective (success rate, ∼90%) and have limited toxicity (∼2% to ∼5%). However, with recurrent episodes of ocular herpes, clinical prob- [16] 0 lems arise, and therapy becomes complicated. When a patient develops HK as a result of reactivation of previous infection with HSV-1, he or she is assigned to receive intense topical and systemic antiviral and anti-inflammatory drug regimens. Although the condition of some patients with chronic HK can be stabilized, many patients do not respond to therapy. These patients have increased stromal opacity (i.e., decreased visual acuity) and increased corneal neovascularization [1, 10, 11] . As noted by Remeijer et al., preoperative steroid treatment of potential PKP patients increased the corneal HSV-1 DNA load and decreased graft survival. Another contributing factor is the clinical nature of the patients who required anti-inflammatory therapy. The clinician is faced with a dilemma. The immune-associated stromal opacity may be stabilized using an anti-inflammatory regimen covered with a potent antiherpetic program [10, 11] . However, the increased neovascularization and the use of steroids both increase the risk of graft failure. This clinical quandary has not been solved. These patients will have a loss of vision if the HK is not treated aggressively. Thus, the corneal transplant has a reduced chance of success, considering these high-risk factors. Effective treatment is needed to block or reduce recurrent episodes of HK. This treatment would consist of (1) an antiviral that would block or significantly reduce neuronal reactivation of HSV-1; (2) a therapy to block or reduce the anterograde transport of the virus from the neuron to the cornea; (3) an anti-inflammatory that could reduce the corneal immune response but would not elicit an increase in the ocular viral load; and (4) a drug to block or significantly reduce corneal neovascularization. However, this ideal combination therapy is not currently available.
How do the data from the study by Remeijer et al. compare with data from similar studies? Table 1 is a summary of data from the study by Remeijer et al. and from 6 other studies. The average percentage of corneas from patients with HK that were positive for HSV-1 DNA was ∼40% (range, 32%-86%). Of the corneas of patients without HK, the average percentage that were positive for HSV-1 DNA was ∼10% (range, 0%-36%). In 5 studies, the viral load was not quantified. Remeijer et al. not only quantified the HSV-1 DNA load per cornea but also collected relevant clinical data on each patient and correlated that data to numerous parameters related to graft survival, as noted above. To our [20] 1/17 (6) 1/17 (6) 1 Kudo et al. (1996) [21] 1/25 (4) knowledge, no other study to date has made all of these comparisons. Detection of HSV-1 DNA in corneas allows us to speculate on the possibility that (1) the cornea is a nonneuronal site of HSV-1 latency and (2) the cornea is a depot for reactivated and transported virions from latent neurons. If the latter possibility is true, then the "dormant" nature of HSV-1 latency is in question. Perhaps knowledge of the "persistent" nature of HSV-1 in neurons and corneas will evolve. Tables 2 and 3 provide summaries of the detection of infectious HSV-1 and HSV-1 DNA in the tears of healthy human volunteers, as detected by cell culture and PCR. For asymptomatic shedding of infectious HSV-1 or HSV-1 DNA, 2 critical factors increase the frequency of detection: the sensitivity of the assay (especially with the use of PCR) and the frequency of collection of tear samples. As early as 1967, Kaufman et al. [12] , in what was, to our knowledge, the first study of its kind, reported the detection of infectious HSV-1 in tears (table 2) . This study included 20 samples per healthy subject, and the results for 4 (36%) of 11 samples were found to be positive at least once during the collection period [12] . Table 3 provides a summary of studies of the asymptomatic shedding of HSV-1 DNA in the tears of healthy humans. In a more recent study by Kaufman et al. [17] , 47 (94%) of 50 subjects were found to be positive for HSV-1 DNA in tears at least once. Tear samples were collected twice daily for 30 consecutive days. Of the 10 studies presented in table 3, only the study by Kaufman et al. [17] determined HSV-1 DNA copy numbers, the range of which was wide (from as low as 4 copies to 124,000 copies per tear sample). Variation in copy numbers suggests a significant difference in the HSV-1 reactivation phenotype.
In a related study, we and other investigators [26] assayed 174 human trigeminal ganglia (TG) and detected HSV-1 DNA in 90% of these neural tissues. We quantified the HSV-1 DNA and found a wide range of copy numbers (from as low as 10 copies to ∼3000 copies per 100 nanograms of host DNA). This finding suggests that the establishment of HSV-1 latency in the TG is highly variable. The high prevalence of HSV-1 DNA in the human TG was not a function of age or sex [26] . Taken together, the data on HSV-1 DNA in tears, corneas, and TG strongly suggest that most humans harbor HSV-1 in one of these locations. In fact, in an editorial, Kaufman [27] posed the question, Does everyone have herpes? The answer is that the vast majority of humans harbor HSV-1.
What does the presence of HSV-1 DNA in the cornea imply? Our perspective is that HSV-1 is latent in the corneas of patients with HK. In fact, Gordon et al. [28] proposed that HSV-1 was latent in corneas. What does the presence of HSV-1 DNA in the corneas of patients without HK and in eye bank corneas imply? Perhaps the virus is not latent in these patients without HK but, rather, is "passing through" after neuronal reactivation. This conclusion is based in part on the high frequency (∼90%) of HSV-1 DNA shedding in human subjects without active herpetic ocular disease [17] , as well as on the finding that ∼90% of human TG contain HSV-1 DNA [26] . The article by Remeijer et al. has important clinical relevance and substantially contributes to our understanding of HK and PKP.
